Atea Pharmaceuticals(AVIR) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Atea Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update Topline SVR12 Results from Global Phase 2 Hepatitis C Virus (HCV) Study (N=275) Expected Q4'24 New Data Supportive of HCV Combination to be Presented at the American Association for the Study of Liver Diseases' (AASLD's) The Liver Meeting 2024 Pharmacokinetic Data for Bemnifosbuvir to be Presented at American College of Pharmacometrics Meeting Conference Call at 4:30 pm ET Today BOSTON, Mass., Novembe ...